Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Merck MRK boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.

Merck’s MRK stock has risen 30.4% this year so far compared with an increase of 4.3% for the industry. An ongoing recovery from the disruptions related to the pandemic and strong global underlying ...

Vree TM for Diabetes 2.0 Helps Patients Manage Their Condition and Facilitates Communication with Healthcare Providers Merck today announced the launch of a mobile application designed to be used by ...

I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular ...

Weeks after Pfizer announced that it would acquire Wyeth, another large drug maker has announced major acquisition plans. Merck & Co. announced Monday that it would buy Kenilworth, N.J.-based Schering ...

FRANKFURT, Nov 13 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a slight gain in third-quarter operating earnings that beat market expectations, benefiting from legislative ...